Publications by authors named "Martin Cannon"

Claim this Profile
M
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models.
Mulu Z Tesfay, Aleksandra Cios, Khandoker Usran Ferdous, Randal S Shelton, Bahaa Mustafa, Martin J Cannon

Front Immunol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic tumor microenvironment reprogramming via alloantigenexpressing virotherapy elicits tumor rejection and improves immunotherapy response.
Mulu Z Tesfay, Aleksandra Cios, Zetao Cheng, Khandoker U Ferdous, Randal S Shelton, Martin J Cannon

bioRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer.
Martin J Cannon, Jia Liu

Viruses· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade.
Mulu Z Tesfay, Yuguo Zhang, Khandoker U Ferdous, Mika A Taylor, Aleksandra Cios, Martin J Cannon

Mol Ther Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Neoadjuvant Virotherapy's Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer.
Khandoker Usran Ferdous, Mulu Z Tesfay, Aleksandra Cios, Randal S Shelton, Conner Hartupee, Martin J Cannon

Biomedicines· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade.
Yan Luo, Barath Shreeder, James W Jenkins, Huashan Shi, Purushottam Lamichhane, Martin J Cannon

J Immunother Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers.
Bolni Marius Nagalo, Yumei Zhou, Emilien J Loeuillard, Chelsae Dumbauld, Oumar Barro, Martin J Cannon

Hepatology· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy.
Yuguo Zhang, Musa Gabere, Mika A Taylor, Camila C Simoes, Chelsae Dumbauld, Martin J Cannon

Front Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages.
Steven J Conrad, Tahseen Raza, Erich A Peterson, Jason Liem, Richard Connor, Martin Cannon

PLoS Pathog· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients.
Matthew S Block, Allan B Dietz, Michael P Gustafson, Kimberly R Kalli, Courtney L Erskine, Martin J Cannon

Nat Commun· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking.
Samir V Jenkins, Michael S Robeson, Robert J Griffin, Charles M Quick, Eric R Siegel, Martin J Cannon

Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy.
Martin J Cannon, Matthew S Block, Lauren C Morehead, Keith L Knutson

Immunotherapy· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Further clinical advancement of dendritic cell vaccination against ovarian cancer.
Lauren C Morehead, Martin J Cannon

Ann Res Hosp· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of alum sludge with peat for aqueous glyphosate removal for maximizing their value for practical use.
Yae Wang, Baiming Ren, Yaqian Zhao, Anthony English, Martin Cannon

Water Sci Technol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory T Cells in Gynecologic Cancer.
Yang Ou, Martin J Cannon, Mayumi Nakagawa

MOJ Immunol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.
Purushottam Lamichhane, Lavakumar Karyampudi, Barath Shreeder, James Krempski, Deborah Bahr, Martin J Cannon

Cancer Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer.
Heba Allam, Blake P Johnson, Mao Zhang, Zhongpeng Lu, Martin J Cannon

J Biol Chem· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model.
Bernice Nounamo, Jason Liem, Martin Cannon, Jia Liu

Mol Ther Oncolytics· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining and managing expectations for early immunotherapy cancer trials.
Thomas Kieber-Emmons, Angela Pennisi, Anna Lane, Eric Siegel, Martin Cannon

Rev Recent Clin Trials· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages.
Martin J Cannon, Debopam Ghosh, Swetha Gujja

Vaccines (Basel)· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer.
Leonardo Mirandola, Yuefei Yu, Martin J Cannon, Marjorie R Jenkins, Rakhshanda L Rahman

Gynecol Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase.
Hannah E Goyne, Pamela J B Stone, Alexander F Burnett, Martin J Cannon

J Immunother· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer.
Hannah E Goyne, Martin J Cannon

Front Immunol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen.
Martin J Cannon, Hannah E Goyne, Pamela J B Stone, Laura J Macdonald, Lindsey E James

Cancer Immunol Immunother· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The case for HER2/neu as a therapeutic target for gynecologic malignancies.
Hannah E Goyne, Martin J Cannon

Immunotherapy· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis